mcpyv tag-specific polyclonal autologous cd8-positive t cells
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2013 (NCT01758458)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- T-lymphocytesSupplementation
T-lymphocytes supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mcpyv tag-specific polyclonal autologous cd8-positive t cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02584829 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2015 | Merck Serono, National Cancer Institute (NCI), University of Washington |
| NCT01758458 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2013 | National Cancer Institute (NCI), University of Washington |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 2013 |
| University of Washington | Academic/Hospital | 2 | 2 | 1 | 2013 |
| Merck Serono | For profit | 1 | 0 | 1 | 2015 |
3 organizations
Page 1 / 1